Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma by Pier Luigi Zinzani, Vincent.

Slides:

Advertisements

Similar presentations

Moskowitz CH et al. Proc ASH 2014;Abstract 290.

Advertisements

Wilson WH et al. Proc ASH 2012;Abstract 686.

Belinostat, a Novel Pan-Histone Deactylase Inhibitor (HDACi), in Relapsed or Refractory Peripheral T-Cell Lymphoma: Results from the BELIEF Trial1 Belinostat.

Lesokhin AM et al. Proc ASH 2014;Abstract 291.

Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.

Efficacy of Denileukin Diftitox Retreatment in Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response 1 Identification of an Active,

Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.

A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results in Patients with DLBCL.

Sequential Dose-Dense R-CHOP Followed by ICE Consolidation (MSKCC Protocol ) without Radiotherapy for Patients with Primary Mediastinal Large B Cell.

Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma.

A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.

Moskowitz CH et al. Proc ASH 2014;Abstract 673.

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

Phase II Study: Pembrolizumab + Pomalidomide/Dexamethasone for Patients With R/R MM New Findings in Hematology: Independent Conference Coverage* of ASH.

KEYNOTE-021: Pembrolizumab + Ipilimumab Active in Previously Treated Advanced NSCLC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

Critical Reviews in Oncology / Hematology

Moskowitz CH et al. Proc ASH 2015;Abstract 182.

Korde N et al. Proc ASH 2012;Abstract 732.

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.

KEYNOTE-087: Pembrolizumab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma New Findings in Hematology: Independent Conference Coverage.

Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood.

KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis.

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

How I treat elderly patients with myeloma

Nonmyeloablative conditioning for relapsed follicular lymphoma

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin.

by Alexander Röth, Andreas Hüttmann, Russell P

SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group by Yok-Lam Kwong, Won Seog Kim, Soon Thye.

Comparison Of R-CHOP14 and R-CHOEP14 As First Line Treatment In Young Patients With High-Risk (aaIPI 2-3) Diffuse Large B-Cell Lymphoma (DLBCL): A Joint.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases by Massimo Federico, Umberto Vitolo, Pier Luigi Zinzani,

Primary testicular lymphoma

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma by Robert Marcus, Kevin Imrie, Andrew Belch,

How I treat refractory CLL

Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma.

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T

Efficacy of Reduced-Intensity Allogeneic Stem Cell Transplantation in Chemotherapy- Refractory Non-Hodgkin Lymphoma Robert M. Dean, Daniel H. Fowler,

Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients.

Response to Carfilzomib Therapy

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood.

Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study by Craig H. Moskowitz, Pier.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia by Benjamin L. Lampson, Haesook T. Kim, Matthew.

Treatment versus Transplant for Challenging Hematologic Disorders

How I treat refractory and early relapsed acute myeloid leukemia

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Linear correlationa between TMB cutoff for ORb for CR/PR rates and HRc for PFS, and OS depending on TMB for patients treated with anti-PD-1/PD-L1 monotherapy.

by Richard L. Piekarz, Robin Frye, H. Miles Prince, Mark H

by Lapo Alinari, and Kristie A. Blum

Genomic determinants of response to cytotoxic chemotherapy.

Survival, subsequent therapies, and response.

SD-101 and low-dose radiation induces responses in patients with indolent lymphoma. SD-101 and low-dose radiation induces responses in patients with indolent.

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML by Ronan T. Swords, Steven Coutre, Michael.

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Is Skull-Base to Proximal Thigh PET/CT Enough

Presentation transcript:

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma by Pier Luigi Zinzani, Vincent Ribrag, Craig H. Moskowitz, Jean-Marie Michot, John Kuruvilla, Arun Balakumaran, Yayan Zhang, Sabine Chlosta, Margaret A. Shipp, and Philippe Armand Blood Volume 130(3):267-270 July 20, 2017 ©2017 by American Society of Hematology

Treatment response in the 16 pembrolizumab-treated patients with rrPMBCL who were evaluable (by imaging) for efficacy at the time of data cutoff. Treatment response in the 16 pembrolizumab-treated patients with rrPMBCL who were evaluable (by imaging) for efficacy at the time of data cutoff. (A) Best percentage change from baseline in target lesions. (Number at the end of each bar indicates the patient identification number.) (B) Transplant eligibility, treatment duration, investigator-assessed response to treatment, and duration of response. (Unless indicated otherwise, patients had stable disease.) PD, progressive disease; PR, partial response; SD, stable disease. Pier Luigi Zinzani et al. Blood 2017;130:267-270 ©2017 by American Society of Hematology